ORAMED PHARMACEUTICALS INC. current report, Q2 FY2024

Abrir documento

Business Context and Reporting Period

Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 20, 2024
Reporting Period: Specific event date of June 20, 2024.
Context: The filing reports on a payment received under a Senior Secured Promissory Note issued by Scilex Holding Company ("Scilex") pursuant to a Securities Purchase Agreement dated September 21, 2023.

Key Financial Metrics

Revenue, Profit, and Margins: The filing text does not provide a clear value for revenue, profit, or margins as this is a current report on a specific transaction event, not a periodic financial statement.
Cash Flow: The Company received an additional payment of approximately $10.4 million on June 20, 2024.
Debt and Liquidity:

  • Note Principal Amount: $101,875,000 (issued by Scilex to Oramed).
  • Total Principal Received to Date: $40.0 million as of June 20, 2024.
  • Recent Payment: $10.4 million applied to the third principal payment installment.
  • Payment Obligation Status: The recent payment fulfilled a $20 million payment obligation.

Material Changes

The primary material change is the receipt of the $10.4 million payment from Scilex. This payment brings the cumulative total received under the Note to $40.0 million, satisfying the specific $20 million installment obligation due at that time. No other material changes to financial position or operations are detailed in this specific filing.

Guidance, Outlook, and Risks

Management Commentary: Management confirms the receipt of the payment and the fulfillment of the installment obligation. The filing includes a standard cautionary note regarding forward-looking statements.
Risks and Contingencies:

  • Risk regarding the Company's ability to obtain payment of principal due pursuant to the Note.
  • Potential diversion of management's attention from ongoing business operations.
  • Exposure to potential litigation in connection with the transactions.
Unusual Items: None reported beyond the scheduled debt repayment.

Investor Verification Checklist

  • Verify the remaining principal balance on the $101,875,000 Note after the $40.0 million received.
  • Confirm the schedule and terms for future principal payments under the Note.
  • Review the status of the warrants to purchase Scilex common stock issued alongside the Note.
  • Monitor for any updates regarding the assumption of Sorrento Therapeutics, Inc. obligations by Scilex.